493. ENDURANCE - EffectiveNess of Evusheld for COVID-19 Pre-exposUre PRophylAxis iN ImmunoCompromised PatiEnts – A Pilot Study

BACKGROUND: In December 2021, Evusheld, a cocktail of 2 monoclonal antibodies (mAB), was granted EUA for COVID-19 pre-exposure prophylaxis (PrEP) of immunocompromised patients (Table 1). The EUA was updated June 2022 to recommend repeating a dose every 6 months for patients needing ongoing protectio...

Descripción completa

Detalles Bibliográficos
Autores principales: Polega, James, Brooks, Heather, Emery, Rebecca, Donkin, Joshua D, Fitzgerald, Kevin, SIMEUNOVIC, G O R D A N A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677950/
http://dx.doi.org/10.1093/ofid/ofad500.562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677950/
http://dx.doi.org/10.1093/ofid/ofad500.562

Ejemplares similares